Live tumour imaging company Elephas garners $55M

Elephas, an oncology diagnostics platform, has successfully raised $55 million in Series C funding, reaching a total funding of $116.5 million. The funding round was led by Venture Investors Health Fund and the State of Wisconsin Investment Board, with continued support from existing investors including Northpond Ventures, Moore Strategic Ventures, WARF Ventures, Tao Invest, Sands Capital, and ARCH Ventures. 

Elephas is focused on developing a diagnostics platform that utilises metabolic imaging to predict how a patient will respond to immunotherapy, a cancer treatment that enhances the immune system's ability to fight the disease. The Wisconsin-based company analyses tumour architecture from patient biopsies and tests potential therapies to assess treatment response, aiming to address the critical need for predicting outcomes in immunotherapy and ultimately improving patient access and outcomes.

Immunotherapy, the therapeutic approach Elephas is centred around, is increasingly used to treat various cancer types, although chemotherapy, radiation therapy, and surgery remain more widely utilised, according to the National Cancer Institute. The broader landscape of companies employing emerging technologies in the fight against cancer includes GE Healthcare, which has engaged in strategic partnerships to advance research and product development focused on precision care, AI, and theranostics. 

Theranostics, an emerging technology in precision medicine, combines imaging technology with therapeutic agents to precisely target and destroy cancer cells. GE Healthcare's collaborations, such as the one with Mayo Clinic and the cancer treatment centre BAMF Health, highlight the industry's commitment to advancing therapeutic approaches and improving patient outcomes through innovative technologies.